Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype

• Conditions: Coronary Heart Disease

• Registration Number: NCT01710436
• Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital

Brief Summary

This study is a prospective, observational study to estimate the relationship between dosage of clopidogrel and platelet aggregation in Chinese with different genotype. The investigators suppose both pretreatment dosage of clopidogrel before percutaneous coronary intervention (PCI) and CYP2C19 genotype may effect the platelet aggregation as well as clinical outcome.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-10
• Study First Submitted: 2012-10-15
• Study First Submitted QC: 2012-10-17
• Study First Posted: 2012-10-19
• Status Verified: 2013-05
• Last Update Submitted: 2013-05-16
• Last Update Posted: 2013-05-20
• Primary Completion: 2013-11

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 880

Inclusion Criteria

• accept PCI in Chinese CHD patients
• expected dual antiplatelet therapy (DAPT) at least 6 months

Exclusion Criteria

• another planned PCI within 6 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change from Baseline in platelet aggregation	1 month and 6 months after PCI

Secondary Outcome Measures

Name	Time	Method
Major adverse cardiovascular events (MACE); Bleeding events	6 months after PCI

Trial Locations

Locations (1)

Cardiovascular Institute and Fu Wai Hospital, CAMS & PUMC; 🇨🇳 Beijing, China